Insulin Pens, Syringes, Pumps And Injectors Market Report 2024: Strategies And Recent Developments | Novo Nordisk A/S, Eli Lilly and Company, Medtronic plc, Abbott Laboratories, Insulet Corporation

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Insulin Pens, Syringes, Pumps And Injectors Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The insulin pens, syringes, pumps and injectors market size has grown strongly in recent years. It will grow from $23.3 billion in 2023 to $25.36 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rising diabetes prevalence, advancements in insulin delivery, patient preference for convenience, aging population.

The insulin pens, syringes, pumps and injectors market size is expected to see strong growth in the next few years. It will grow to $34.41 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to emerging markets growth, regulatory support and reimbursement, personalized medicine, value-based healthcare. Major trends in the forecast period include artificial intelligence (ai) integration, handheld and wireless ultrasound devices, 3d/4d imaging, fusion imaging.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=3806&type=smp

Market Segmentation:
The main types of insulin pens, syringes, pumps, and injector devices and equipment are pens, injectors, pumps, and syringes. The syringe is a device used to inject fluids into or withdraw them from something. The pens used are both reusable and disposable. The pumps used are tube pumps and tubeless pumps. The various end-users are hospitals, home care, and others.d-users are hospitals, home care, and others.

Major Driver - Rising Global Diabetes Prevalence Drives Growth In Insulin Pens, Syringes, Pumps And Injectors Market
An increase in the prevalence of diabetes globally is driving the growth of the insulin pens, syringes, pumps, and injectors market. The increase in the number of people suffering from obesity, unhealthy eating habits, physical inactivity, and the increasing geriatric population are some of the key factors which are leading to the increase in the global prevalence of diabetes. According to the US Centers for Disease Control and Prevention (CDC) in 2020, around 34.2 million people in the U.S. were suffering from diabetes. Also, according to the International Diabetes Federation, in 2021, globally approximately537 million adults were living with diabetes; by 2045, this number would rise to 783 million. Therefore, the increase in the prevalence of diabetes globally is driving the growth of the insulin pens, syringes, pumps, and injectors market.

Competitive Landscape:
Major companies operating in the insulin pens, syringes, pumps and injectors market include Novo Nordisk A/S, Eli Lilly and Company, Medtronic plc, Abbott Laboratories, Insulet Corporation, Sanofi Aventis, F. Hoffmann-La Roche Ltd, Becton Dickinson and Company, Animas Corporation, Ypsomed Holding AG, Dickinson and Company, Valeritas Inc., MannKind Corporation, Tandem Diabetes Care Inc., Biocon Ltd., B. Braun Melsungen AG, Terumo Corporation, Teleflex Incorporated, Nipro Corporation, Smiths Medical Inc., Owen Mumford, UltiMed Inc., Ypsomed Holding, Ascensia Diabetes Care, Trividia Health, ARKRAY Inc., AgaMatrix Inc., Medline Industries LP, Gerresheimer AG, West Pharmaceutical Services Inc., SHL Medical AG, Zhejiang POCTech Medical Co.Ltd., Jiangsu Wanhai Medical Instruments Co. Ltd.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/insulin-pens-syringes-pumps-and-injectors-global-market-report

Top Trend - FDA Approves Omnipod 5 A Revolutionary Step In Safe And Effective Insulin Delivery
Many companies are focusing on technological advancements in insulin delivery systems to deliver insulin effectively and safely. For instance, in September 2022, the FDA approved the use of Omnipod 5 for children over 2 years with type 1 diabetes. Omnipod is the first tubeless automated insulin delivery aid for people with type 1 diabetes.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Insulin Pens, Syringes, Pumps And Injectors Market Characteristics
3. Insulin Pens, Syringes, Pumps And Injectors Market Trends And Strategies
4. Insulin Pens, Syringes, Pumps And Injectors Market - Macro Economic Scenario
5. Insulin Pens, Syringes, Pumps And Injectors Market Size And Growth
…..
27. Insulin Pens, Syringes, Pumps And Injectors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.